SeaStar Medical QUELIMMUNE shows 65% Day 90 survival in paediatric AKI

Post-approval registry data presented at ASN Kidney Week showed QUELIMMUNE more than doubled the odds of 90-day survival versus a historical comparator cohort.

A white circular device rests on a wooden nightstand in a sunlit bedroom, with white bedding and pillows visible in the background.

SeaStar Medical has reported statistically significant survival findings from its post-approval SAVE registry for QUELIMMUNE (SCD-PED), its selective cytopheretic device approved for critically ill children with sepsis-associated acute kidney injury (AKI) requiring continuous renal replacement therapy (CRRT). The data were presented as a late-breaking poster at ASN Kidney Week 2026 in Denver on 22 October.

The primary analysis compared 43 QUELIMMUNE-treated patients from the SAVE registry with 196 clinically aligned patients drawn from the Kids' Inpatient Database (KID), the largest publicly available all-payer paediatric inpatient dataset in the United States. At Day 90, the QUELIMMUNE cohort achieved 65.1% survival against 47.4% in the KID cohort (p = 0.043), representing an odds ratio of 2.07 (95% CI, 1.04–4.11). A Bayesian analysis placed the probability of higher survival in the QUELIMMUNE group at 98.2%. Survival to hospital discharge was also significantly higher in the treated cohort (p = 0.04).

What the data show

A landmark sensitivity analysis, comparing patients alive one day after QUELIMMUNE initiation with KID patients who survived beyond one day of CRRT, showed 63.8% Day 90 survival in the treated group versus 48.7% in the comparator (p = 0.074), representing an estimated 86% higher odds of survival, though this secondary result did not reach conventional frequentist significance. Mortality hazard models consistently favoured the QUELIMMUNE cohort, with hazard ratios ranging from 0.60 to 0.66 across four models, and both Bayesian time-to-death analyses exceeded the 95% posterior probability threshold.

On renal outcomes, 83% of survivors in the QUELIMMUNE cohort who were not RRT-dependent at baseline had achieved RRT independence by Day 90. No device-related adverse events were recorded; bloodstream infections occurring within 28 days of device initiation were adjudicated by an independent data and safety monitoring board as unrelated to QUELIMMUNE.

Stuart Goldstein, Director of the Centre for Acute Care Nephrology at Cincinnati Children's and a paid member of the SeaStar Medical Scientific Advisory Board, said the consistency of the survival signal across multiple analytic approaches "support continued and further exploration of these and additional data that is forthcoming from new patients."

Registry limitations and broader context

The findings carry important caveats. This is an observational, external-control study, not a randomised controlled trial, and the comparator derives from 2019 and 2022 administrative database records rather than prospectively enrolled controls. Baseline differences between the two groups may not be fully captured by clinical alignment, and the QUELIMMUNE cohort is small at 43 to 47 patients depending on the analysis.

QUELIMMUNE received FDA approval in February 2024 under a Humanitarian Device Exemption, a regulatory pathway that requires demonstration of safety and probable benefit rather than full effectiveness. The HDE label carries a statutory disclosure that effectiveness has not been demonstrated, a material distinction for clinicians and procurement committees weighing adoption.

Sepsis-associated AKI in children is an ultra-rare, high-mortality condition with no other FDA-approved device or pharmacological therapy targeting the underlying hyperinflammatory mechanism. That near-absence of competition makes the QUELIMMUNE survival signal clinically meaningful even at modest sample sizes, though independent replication remains important. SeaStar is also running the NEUTRALIZE-AKI pivotal trial in 339 adult AKI patients, which uses a full randomised design and could, if positive, substantially broaden the addressable market. Peer-reviewed publication of the SAVE registry findings is expected and will be the next significant milestone for the paediatric programme.